Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
NCT02859961
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
562
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV
Interventions
DRUG:
PRO 140 (350 mg)
DRUG:
PRO 140 (525 mg)
DRUG:
PRO 140 (700 mg)
Sponsor
CytoDyn, Inc.